Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in advanced ovarian cancer
NCT03262545Phase 2Unknown
- Sponsor
- Sichuan Cancer Hospital
- Start
- Aug 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer comparing Apatinib Arm with Placebo Arm (2 arms). Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03262545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03262545.